Clinical Trial Update: A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BPI-1178 in combination with Osimertinib for advanced non-small cell lung cancer with EGFR mutations; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BPI-1178
• Osimertinib (osimertinib)

Snippet

Sponsor: National Cancer Center, China | Conditions: NSCLC | Phase 1 | Status: RECRUITING